IRIS
PIETRA, DANIELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 303
EU - Europa 226
AS - Asia 136
AF - Africa 2
OC - Oceania 1
SA - Sud America 1
Totale 669
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 290
IE - Irlanda 122
CN - Cina 105
FI - Finlandia 34
SG - Singapore 29
DE - Germania 26
IT - Italia 15
SE - Svezia 14
CA - Canada 13
GB - Regno Unito 6
NL - Olanda 4
IN - India 2
MU - Mauritius 2
AT - Austria 1
AU - Australia 1
CL - Cile 1
ES - Italia 1
LT - Lituania 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 669
Salva come PNG Salva come JPEG
Città #
Dublin 122
Chandler 72
Beijing 37
Helsinki 28
New York 28
Ashburn 27
Boardman 18
Singapore 15
Lawrence 14
Princeton 14
Nanjing 13
Toronto 12
Shanghai 11
Wilmington 11
Medford 10
Nanchang 6
Changsha 5
Falkenstein 5
Hangzhou 5
Hebei 5
Jacksonville 5
Jiaxing 5
Gallarate 4
Norwalk 4
Shenyang 4
Washington 4
Falls Church 3
Tianjin 3
Dronten 2
Jinan 2
Monmouth Junction 2
Rome 2
Seattle 2
Woodbridge 2
Berlin 1
Canberra 1
Chongqing 1
Clifton 1
Fairfield 1
Fano 1
Fuzhou 1
Jiangmen 1
Leawood 1
Linyi 1
Los Angeles 1
Milan 1
Modena 1
Montesilvano Marina 1
Ningbo 1
Pavia 1
Pune 1
San Francisco 1
Settimo Torinese 1
Shijiazhuang 1
Vienna 1
Xingtai 1
Totale 524
Salva come PNG Salva come JPEG
Nome #
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 67
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 59
Rap2, but not Rap1 GTPase is expressed in human red blood cells and is involved in vesiculation 56
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 53
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 51
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 47
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 46
Diagnosis and management of prefibrotic myelofibrosis. 46
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 45
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 38
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms 37
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. 35
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. 35
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. 32
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. 32
Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications 15
Totale 694
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.950
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.950
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202055 0 0 0 0 0 0 5 9 8 18 13 2
2020/202122 1 0 1 3 0 1 0 2 9 1 2 2
2021/202277 0 0 12 3 3 3 1 4 4 5 11 31
2022/2023248 26 16 6 8 15 19 0 17 130 3 7 1
2023/2024137 15 30 7 8 5 54 1 10 1 1 3 2
2024/202579 15 18 5 2 4 25 10 0 0 0 0 0
Totale 694